SGLT2 Inhibitors and Chronic Kidney Disease: A Broadening Clinical Perspective

CME: 1.0

Target Audience

Nephrologists and primary care providers. The secondary audiences are endocrinologists, cardiologists, specialists in internal medicine (MDs and DOs), nurse practitioners, physician assistants, nurses, and pharmacists.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the limitations of current preventive strategies and treatments for CKD, along with the residual need to further reduce associated impacts on CVD and overall mortality risk
  • Summarize new evidence supporting the impact of SGLT2 inhibitors on the onset and progression of CKD, including conversion to end-stage renal disease (ESRD), in people with and without diabetes
  • Discuss currently indicated methods to use SGLT2 inhibitors to blunt the progression of CKD, as well as the potential evolution of this usage as additional supportive data are released


Dr. Richard S. Beaser*†

Senior Staff Physician and Medical Director of CME
Joslin Diabetes Center

Kamyar Kalantar-Zadeh, MD, MPH, PhD

Chief, Division of Nephrology
Hypertension and Kidney Transplantation
Tenured Professor of Medicine
Public Health and Nursing Sciences
University of California Irvine
School of Medicine

Muthiah Vaduganathan, MD, MPH

Attending Cardiologist
Brigham and Women’s Hospital
Cardiometabolic Center of Implementation Science
Instructor of Medicine
Harvard Medical School

Physicians Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

Physicians Credit Designation

Enduring Material
Joslin Diabetes Center designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

The faculty and planning committee members for this program have disclosed the following:

Dr. Richard S. Beaser*†, has no relevant financial relationships with regard to this activity.

Kamyar Kalantar-Zadeh, MD, MPH, PhD

  • Consultant: AstraZeneca.

Muthiah Vaduganathan, MD, MPH

  • Received grant/research support: Amgen, American Regent, AstraZeneca, Baxter Healthcare, Boehringer Ingelheim / Eli Lilly, Bayer AG, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa
  • Consultant: Amgen, American Regent, AstraZeneca, Baxter Healthcare, Boehringer Ingelheim / Eli Lilly, Bayer AG, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa
  • Promotional Activities’ Speaker: Novartis and Roche Diagnostics.

Planning Committee

Carole Drexel, PhD, Medical Director, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.

Jaimee Harris-Gold, Program Manager, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.

Joslin CME Advisory Committee

Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.

Nuha El Sayed, MD, Staff Physician and Medical Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.

Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.

Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.

Alissa Segal, Pharm D, CDE, CDTC, FCCP, Clinical Pharmacist, Joslin Diabetes Center, has no relevant financial relationships.

Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships

Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* Also on the Planning Committee
† Also on the CME Advisory Committee

Method of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that these modules will take approximately 1 hour and 45 minutes to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Contact Information
Please send content inquiries to:

For technical problems with the site or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at or DiabetesSeriesLive at 877-394-1306 or at

Disclaimers (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, CardioCareLive, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting with the subject line “Data Request”

Post a comment to this article